Upifitamab (CAS 2254118-43-7) is a monoclonal antibody that targets NaPi2b, a protein overexpressed in cancers like platinum-resistant recurrent ovarian cancer, to inhibits tumor growth and boosts immune destruction. It helps create antibody-drug conjugates (ADCs). Upifitamab rilsodotin, an ADC targeting NaPi2b, is used in ovarian cancer research, especially for platinum-resistant recurrent ovarian cancer.
Key Features:
- Target Specificity: Binds to NaPi2b on tumor cells.
- Mechanism of Action: Inhibits tumor growth and enhances immune destruction.
- Conjugate: Combined with a cytotoxic agent in ADCs.
Applications:
- Cancer Therapy: Targets NaPi2b-expressing tumors, including platinum-resistant ovarian cancer.
- ADCs: Used for targeted therapy.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.
